



UNITED STATES PATENT AND TRADEMARK OFFICE

NOV 18 2009

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

Jeffrey P. Kushan  
Sidley Austin, LLP  
1501 K Street, N.W.  
Washington, DC 20005

Re: Patent Term Extension  
Application for  
U.S. Patent No. 6,884,879

WITHDRAWAL OF APPLICATION FOR PATENT TERM EXTENSION

This is in response to the "Election Under 37 C.F.R. § 1.785(b)" filed April 24, 2009, of the application for patent term extension for U.S. Patent No. 6,407,213, (LUCENTIS® (ranibizumab)). The present application for patent term extension for U.S. Patent No. 6,884,879 is withdrawn in favor of the elected patent, U.S. Patent No. 6,407,213.

The present application is hereby withdrawn from consideration and dismissed.

Any correspondence with respect to this matter should be addressed as follows:

By mail: Mail Stop Hatch-Waxman PTE  
P.O. Box 1450  
Alexandria, VA 22313-1450

Telephone inquiries related to this determination should be directed to the undersigned at (571) 272-7755. E-mail inquiries should be directed to [mary.till@uspto.gov](mailto:mary.till@uspto.gov).

Mary C. Till  
Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: Office of Regulatory Policy  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 51, Rm. 6222  
Silver Spring, MD 20993-0002

RE: LUCENTIS® (ranibizumab)  
FDA Docket No.: FDA-2007-E-0165

Attention: Beverly Friedman